InvestorsHub Logo
Followers 30
Posts 4329
Boards Moderated 0
Alias Born 03/20/2011

Re: None

Tuesday, 06/27/2023 2:24:24 PM

Tuesday, June 27, 2023 2:24:24 PM

Post# of 110
https://www.precisionmedicineonline.com/cancer/astrazeneca-q1-oncology-product-sales-increase-14-percent-led-tagrisso

The EGFR-inhibiting lung cancer treatment Tagrisso (osimertinib) continued to be AstraZeneca's top-selling oncology product in Q1 2022, with revenues growing 14 percent to $1.30 billion from the prior year's quarter. The company is looking to expand the drug's indications, such as for refractory, advanced non-small cell lung patients who have already received and progressed on Tagrisso due to acquired MET overexpression or amplifications.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BDTX News